[1]高自颖,何玲鸽,甄拴平.血清骨代谢标志物实验室检测基于生物学变异的允许总误差在可比性验证中的应用[J].现代检验医学杂志,2022,37(06):192-197.[doi:10.3969/j.issn.1671-7414.2022.06.037]
　GAO Zi-ying,HE Ling-ge,ZHEN Shuan-ping.Application of Allowable Total Error Based on Biological Variation in Comparability Verification of Serum Bone Metabolism Markers in Laboratory Detection[J].Journal of Modern Laboratory Medicine,2022,37(06):192-197.[doi:10.3969/j.issn.1671-7414.2022.06.037]
点击复制

血清骨代谢标志物实验室检测基于生物学变异的允许总误差在可比性验证中的应用()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年06期
页码:
192-197
栏目:
质量控制·实验室管理
出版日期:
2022-11-15

文章信息/Info

Title:
Application of Allowable Total Error Based on Biological Variation in Comparability Verification of Serum Bone Metabolism Markers in Laboratory Detection
文章编号:
1671-7414(2022)06-192-06
作者:
高自颖1; 何玲鸽1; 甄拴平2
(1. 宝鸡市中心医院检验科，陕西宝鸡 721008；2. 宝鸡市中医医院检验科，陕西宝鸡 721001)
Author(s):
GAO Zi-ying1;  HE Ling-ge1;  ZHEN Shuan-ping2
(1.Department of Clinical Laboratory, Baoji Central Hospital, Shaanxi Baoji 721008, China; 2.Department of Clinical Laboratory, Baoji Hospital of Traditional Chinese Medicine, Shaanxi Baoji 721001, China)
关键词:
骨代谢标志物; 允许总误差;  可比性验证
分类号:
R446
DOI:
10.3969/j.issn.1671-7414.2022.06.037
文献标志码:
A
摘要:
目的 通过分析血清骨代谢标志物实验室检测项目基于生物学变异的允许总误差(total error,TEa)质量指标与基于室间质量评价(external quality assessment, EQA)TEa 质量指标在实验室可比性验证中的结果，评价基于生物学变异的TEa 质量指标在血清骨代谢标志物室内、外可比性验证中的实用性。方法 收集宝鸡市中心医院2021 年11~12 月血清骨代谢标志物试剂更换批次可比性验证数据，同时收集相同项目2021 年第2 次实验室间比对数据，计算相对偏差。项目包括骨钙素、总Ι 型胶原氨基端延长肽(TP1NP)、β- 胶原特殊序列(β-CTX)、甲状旁腺素(PTH)和25-羟维生素D3[D3(25-OH)]。通过王治国主编《临床检验生物学变异与参考区间》附录获取血清骨代谢标志物基于生物学变异的TEa 质量指标，以国家卫生健康委临床检验中心2021 年第2 次EQA 反馈报告，获取EQA 的TEa 质量指标，将可比性验证数据用此两种来源质量指标做符合要求率判断，以P ＜ 0.05 为差异有统计学意义。结果 以基于EQA 或专家推荐的TEa 为质量标准，血清骨代谢标志物试剂更换批号、室间比对的5 个项目的符合要求率均为100% , 可比性验证全部通过。以基于生物学变异TEa 的最低质量标准判断，试剂更换批号、室间比对符合要求率80%~100% , 两种来源判断标准结果比较符合要求率的差异无统计学意义(χ2 ≥ 1.000，均P ＞ 0.05), 可比性验证通过。以基于生物学变异TEa 适当质量标准判断，则5 个项目符合要求率为20%~100%，β-CTX，骨钙素试剂更换批号比对符合要求率分别为20% 和40%，差异有统计学意义(χ2=0.048，0.246，均P ＜ 0.05), 可比性验证不能通过；此时室间比对的符合要求率60%-100%，差异无统计学意义(χ2=0.444~1.000，均P ＞ 0.05)，但符合率60% 的β-CTX 可比性验证不能通过。结论 血清骨代谢标志物实验室检测基于生物学变异的TEa 质量指标可以通过生物学变异数据库获得[D3(25-OH) 除外]，有3 级性能指标，更科学、更严谨，建议实验室首选应用。
Abstract:
Objective To verify the comparability between the total error (TEa) quality index based on biological variation and the TEa quality index based on external quality assessment (EQA) in the laboratory testing items of serum bone metabolism markers. The results in this study were used to evaluate the utility of biological variation-based TEa quality indicators in the validation of serum bone metabolism markers in vitro and in vivo comparability. Methods The comparability verification data of replacement batches of serum bone metabolism marker reagents in Baoji Central Hospital from November to December 2021 were collected, and the second inter-laboratory comparison data of the same project in 2021 was collected to calculate the relative deviation. Items include osteocalcin, total collagen type 1 amino-terminal extension peptide (TP1NP), β-collagen specific sequence (β-CTX), parathyroid hormone (PTH) and 25-hydroxyvitamin D3 [D3(25-OH)] . Obtain the TEa quality index of serum bone metabolism markers based on biological variation through the appendix of Clinical Testing Biological Variation and Reference Interval edited by WANG Zhiguo, and obtain the TEa quality index of EQA based on the second EQA feedback report of the National Center for Clinical Laboratory in 2021. The comparability verification data were judged by these two source quality indicators as the compliance rate, and P < 0.05 was considered to be statistically significant. Results With the quality standard based on EQA or TEa recommended by experts, the compliance rates of the five items of serum bone metabolism marker reagent replacement batch number and inter-laboratory comparison were all 100%, and the comparisons were all passed. Judging by the minimum quality standard based on biological variation TEa, the compliance rate of reagent replacement batch number and inter-laboratory comparison was 80%~100%, and the difference in compliance rate between the two source judgment standards was not statistically significant (χ2 ≥ 1.000, all P > 0.05), the comparison was passed. Judging by the appropriate quality standard based on biological variation TEa, the compliance rate of 5 items was 20%~100%, and the compliance rates of β-CTX and osteocalcin reagent replacement batch numbers were 20% and 40%, respectively, with the differences were statistically significant (χ2 = 0.048, 0.246, all P < 0.05), the comparison failed. The compliance rate of the inter-laboratory comparison was 60%~100%, and the differences were not statistically significant (χ2 = 0.444~1.000, all P > 0.05), but the β-CTX alignment with a coincidence rate of 60% could not pass. Conclusion The TEa quality indicators based on biological variation in the laboratory detection of serum bone metabolism markers could be obtained through the biological variation database [except D3(25-OH)]. There are three-level performance indicators, which are more scientific and more rigorous. Recommended laboratory preferred application.

参考文献/References:

[1] 王治国 . 临床检验方法确认与性能验证 [M]. 北京 : 人民卫生出版社 ,2009: 91-92. WANG Zhiguo. Clinical test method validation and performance validation[M]. Beijing: People’s Health Publishing House,2009: 91-92.
[2] Clinical and Laboratory Standards Institude. User evaluation of between-reagent lot variation；Approved Guideline [S]. Wayne: PA, CLSI EP26-A, 2013.
[3] Clinical and Laboratory Standards Institude. Validation of comparability of patient results within one health care system；Approved Guideline(Interim Revision)[S]. Wayne: PA, CLSI EP31-A, 2018.
[4] 王治国 .临床检验生物学变异与参考区间 [M].北京 : 人民卫生出版社 ,2012: 215-232. WANG Zhiguo. Clinical test biological variation and reference interval [M]. Beijing: People’s Health Publishing House, 2012: 215-232.
[5] 国家卫生健康委员会临床检验中心 .2021年内分泌第 2次室间质评统计结果表(2020标准) : 计划编码 NCCL-C-07 [EB]. [2021-11-03].https://www.nccl. org.cn/maincn 00900842346327.pdf. National Center for Clinical Laboratories. Table of statistical results of the second endocrine interventricular quality assessment in 2021 (2020 criteria) : Planned code NCCL-C-07[EB]. [2021-11-03]. https://www.nccl.org.cn/maincn 00900842346327.pdf
[6] 中国合格评定国家认可委员会 . CNAS-CL02-A003: 医学实验室质量和能力认可准则在临床化学检验领域的应用说明 [S]. 北京 : 中国标准出版社 ,2018. China National Accreditation Service for Conformity Assessment . CNAS-CL02-A003: Guidance on the application of accreditation criteria for the medical laboratory quality and competence in the field of clinical chemistry[S]. Beijing: China Standard Press, 2018.
[7] 康凤凤 ,张传宝 ,王薇 . 等 . 正确度验证计划在六西格玛性能评价中的应用 [J]. 临床检验杂志 , 2014, 32(2): 130-132. KANG Fengfeng, ZHANG Chuanbao, WANG Wei, et al. Application of trueness verification scheme in six sigma metric analysis [J]. Chinese Journal of Clinical Laboratory Science,2014,32(2):130-132.
[8] 王治国 . 临床检验质量控制技术 [M]. 2版 . 北京 : 人民卫生出版社 , 2008: 62-63. WANG Zhiguo. Clinical inspection quality control technology [M]. 2nd Ed. Beijing: People’s Health Publishing House, 2008: 62-63.
[9] 中华人民共和国国家卫生健康委员会 .WS/T 407-2012:医疗机构内定量检验结果的可比性验证指南 [S].北京 : 中国标准出版社 .2012. National Health Commission of the People’s Republic of China. WS/T 407-2012: Guidelines for comparability verification of quantitative results with in one health care system [S]. Beijing: China Standard Press, 2012.

相似文献/References:

[1]张 路,王 薇,王治国.国内两种允许总误差标准在评估临床化学检测项目分析质量及选择质控程序中的应用比较[J].现代检验医学杂志,2015,30(03):162.[doi:10.3969/j.issn.1671-7414.2015.03.050]
　ZHANG Lu,WANG Wei,WANG Zhi-guo.Application Comparison of Two Source of Allowable Total Errors in σ Metrics Assessing the Analytical Quality and Selecting Quality Control Procedures for Automated Clinical Chemistry[J].Journal of Modern Laboratory Medicine,2015,30(06):162.[doi:10.3969/j.issn.1671-7414.2015.03.050]
[2]闫玉珠,王冀邯,赵和平.六西格玛质量管理规则在罗氏电化学发光免疫分析仪检测项目质量控制中的应用[J].现代检验医学杂志,2020,35(02):149.[doi:10.3969/j.issn.1671-7414.2020.02.041]
　YAN Yu-zhu,WANG Ji-han,ZHAO He-ping.Six Sigma Quality Management for Choosing Appropriate Quality ControlRules in Roche Electrochemical Luminescence Immunoanalyzer[J].Journal of Modern Laboratory Medicine,2020,35(06):149.[doi:10.3969/j.issn.1671-7414.2020.02.041]

备注/Memo

备注/Memo:
作者简介：高自颖(1972-)，女，本科，主任检验技师，研究方向：临床免疫学检验，E-mail:gzy19721011@126.com。
通讯作者：甄拴平，男，本科，主任检验技师，研究方向：临床微生物学与分子生物学检验，E-mail:bjzyzsp@126.com。
更新日期/Last Update: 2022-11-15